SEC Form 4 · accession 0001209191-17-007221
PUMA BIOTECHNOLOGY, INC. · PBYI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Charnas
Other
Period of report
Feb 1, 2017
Accepted (ET)
Feb 2, 2017 · 5:43 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001401667
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| COMMON STOCK | Feb 1, 2017 | S | 1,000 | $31.80 | D | 28,461 | D | |
| COMMON STOCK | Feb 1, 2017 | S | 2,008 | $31.85 | D | 26,453 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 15, 2016.
Remarks
The Reporting Person is the Senior Vice President of Regulatory Affairs and Project Management of the Issuer.